QIAGEN and CENTOGENE to collaborate in bioinformatics for genetic diseases

Aiding the analysis of hereditary disorders by integrating genomic and clinical databases

11-Oct-2017 - QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing ...

Bristol-Myers Squibb and QIAGEN collaborate

Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies

07-Jun-2017 - Bristol-Myers Squibb Company and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer ...

QIAGEN and Biotype Diagnostics form partnership

30-Jun-2015 - QIAGEN and Biotype Diagnostics GmbH announced that they have entered into a partnership to establish Biotype Innovation GmbH ("Biotype Innovation"). The new company will develop and commercialize molecular diagnostic workflows initially for personalized healthcare applications based on QIAGEN’s ...

QIAGEN makes proposal to fully acquire Ipsogen

16-Jun-2011 - QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully acquire a global leader in molecular profiling and personalized healthcare diagnostics for a broad range of hematological (blood) ...

QIAGEN makes proposal to acquire Australian diagnostics company Cellestis Limited

04-Apr-2011 - QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million (US$355 million) in cash, providing QIAGEN with access to a novel “pre-molecular” technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.The ...

QIAGEN Expands Partnership with Genome Diagnostics for Development of Tests in Prevention and Personalized Healthcare

Extended HLA testing portfolio includes products to assess tolerance for Lumiracoxib and for the early detection of inflammatory diseases

21-Jun-2010 - QIAGEN announced that it has entered into an agreement with the Dutch molecular diagnostic component supplier Genome Diagnostics which covers the development and commercialization of 6 new tests until 2011. QIAGEN believes that this collaboration will further expand the Company’s testing ...

QIAGEN Acquires Exclusive Licence for Key PI3K gene

Patent licensed from Johns Hopkins University for PCR-based companion diagnostics for cancer treatments

10-Feb-2010 - QIAGEN announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a ...

QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients

05-Feb-2010 - Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of ...

QIAGEN to Acquire SABiosciences

11-Nov-2009 - QIAGEN N.V. announced that it has signed a definite agreement to acquire SABiosciences Corporation, a privately-held developer and manufacturer of disease- and pathway-focused PCR assay panels. SABiosciences is based in Frederick, Maryland (USA), and employs a staff of around 100. The ...

QIAGEN Acquires DxS Ltd

24-Sep-2009 - QIAGEN N.V. announced that it has acquired DxS Ltd (DxS), a privately-held developer and manufacturer of companion diagnostic products headquartered in Manchester, United Kingdom. The transaction is valued at approximately US$ 95 million in cash (subject to customary purchase price adjustments), ...